POSTER SESSIONS ABSTRACTS
Poster Session XI
P-11
ANTIBACTERIAL AND ANTIVIRAL CHEMOTHERAPY, ANTINEOPLASTIC DRUGS
| P-11/1 | Chronic stress affects lung
sphingosine kinase isoenzymes and increases the risk of lung bacterial
infections V. Lucini, M. Pannacci, S. Dugnani, F. Scaglione (Milano) |
| P-11/2 | Effects of
itraconazole on the pharmacokinetics of ciprofloxacin and the intestinal
metabolizing system (CYP450 and P-glycoprotein) A. Benini, T. Della Bora, E. Bertazzoni Minelli (Verona) |
| P-11/3 | Population pharmacokinetics of daptomycin in patients affected by
Gram-positive infections M. Polillo, C. Tascini, M. Lastella, G. Gemignani, L. Ciofi, V. Sarli, F. Menichetti, R. Danesi, A. Di Paolo (Pisa) |
| P-11/4 | Peg-Interferon
/ Telbivudine sequential therapy in e antigen (HBeAg) negative severe chronic
hepatitis B. L. Gallelli, O. Staltari, B. Caroleo, V. Guadagnino, G. De Sarro (CATANZARO) |
| P-11/5 | Bilirubin: an endogenous molecule
with antiviral activity in vitro. R. Santangelo, C. Mancuso, S. Marchetti, E. Barone, R. Siciliano, G. Fadda (Roma) |
| P-11/6 | Linezolid
tailored therapy through therapeutic drug monitoring in a patient with nocardiosis assuming p-glycoprotein (P-gp) inhibitors P.G. Cojutti, F. Pea, A. Pagotto, F. Cristini, P. Viale, M. Furlanut (Udine, Bologna) |
| P-11/7 | Therapeutic drug monitoring
(TDM)-guided therapy in three-times weekly teicoplanin treatment for chronic
infections PG. Cojutti, F. Pea, B. Del Pin, B. Cadeo, M. Furlanut ( |
| P-11/8 | Linezolid plasma concentrations
and occurrence of drug-related side effects in patients with gram-positive
infections S. Fucile, V. Cozzi, S. Baldelli, G. Orlando, E. Clementi, D. Cattaneo (Milano, Bergamo) |
| P-11/9 | "In
vitro" Evaluation of the Antimycotic Activity of Glabridin on
Multi-resistant Candida Strains T. Rossi, A.I. Ruberto, L. Baroni, E. Bortolazzi, A. Fabio (Modena) |
| P-11/10 | Antifungal
Activity of Some Essential Oils against Multi-Resistant Candida Strains T. Rossi, S. Benvenuti, F. Pellati, A.I. Ruberto, E. Bortolazzi, L. Baroni, A. Fabio (Modena) |
| P-11/11 | Botanicals used as food supplements interfering with
EphA2-ephrinA1 system: a screening study C. Giorgio, I. Hassan Mohamed, R. Bruni, L. Flammini, E. Barocelli, A. Guerrini, S. Bertoni, M. Tognolini (Parma, Ferrara) |
| P-11/12 | Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase
activation I. Hassan Mohamed, C. Giorgio, L. Flammini, E. Barocelli, M. Incerti, A. Lodola, M. Tognolini (Parma) |
| P-11/13 | Antitumor effects
of novel co-drugs linking histone deacetylaseand ribonucleotide
reductaseinhibitors in hematological tumors A. Ferro, L. Cappellacci, A. Mingrino, R. Petrelli, M. Tolomeo, P. Vita, N. D\\\'Alessandro, L. Dusonchet, P. Franchetti, M. Grifantini, M. Meli (Palermo, Camerino) |
| P-11/14 | Mithocondria defect and cisplatin
resistance: relationships on ovarian cancer cells. M. Montopoli, M. Bellanda, E. Ragazzi, D. Catanzaro, G. Froldi, S. Mammi, L. Caparrotta (Padova) |
| P-11/15 | Circulating
levels of EGFR endogenous ligands as pharmacodynamic markers of EGFR
inhibition by cetuximab in combination with irinotecan in metastatic
colorectal cancer (mCRC) G. Bocci, C. Cremolini , A. Fioravanti, P. Orlandi, L. Salvatore , G. Masi, M. Schirripa, B. Canu, T. Di Desidero, G. Fontanini, F. Basolo, R. Danesi , A. Falcone, F. Loupakis (Pisa) |
| P-11/16 | Antiangiogenic
and antitumour activity of CLM3, a novel multiple tyrosine kinase inhibitor,
alone and in combination with SN-38 A. Fioravanti, C. |
| P-11/17 | Pharmacokinetic and pharmacodynamic evaluations of metronomic
uracil/tegafur (UFT), cyclophosphamide (CTX) and celecoxib (CXB) in patients
with advanced refractory gastrointestinal cancers T. Di Desidero, G. Allegrini, MT. Barletta, A. Fioravanti , P. Orlandi, B. Canu, S. Chericoni, A. Di Paolo, F. Loupakis, G. Masi, M. Giusiani, M. Del Tacca, RS. Kerbel, A. Falcone, R. Danesi, G. Bocci (Pisa, Toronto) |
| P-11/18 | Maesopsin 4-O-β-D-glucoside (TAT-2), a natural
compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation of acute
myeloid leukemia. N. Pozzesi, S. Pierangeli, C. Riccardi, D.V. Delfino (Perugia) |
| P-11/19 | HDAC inhibitors induce NIS expression in testicular cells of carcinoma V. Maggisano, M. Celano, M. D'Agostino, G. Tamburrano, A. Verrienti, M.V. Dima, S. Micali, G. Isgrò, G. Sammarco, M. Sponziello, C. Durante, R. Sacco, D. Russo (Catanzaro, Roma, Modena) |
| P-11/20 | Two marine sesterterpenoids
induce apoptosisin human carcinoma cells D. De Stefano, G. Tommonaro, S. De Rosa , G. Kroemer, M.C. Maiuri, R. Carnuccio (Napoli, Pozzuoli (NA), Villejuif (Parigi, Francia)) |
| P-11/21 | Possible
mechanisms of Raf-1 Kinase Inhibitor Protein down-regulation in
hepatocellular carcinoma M. Notarbartolo, P. Poma , N. Vivona , M. Labbozzetta, R. Porcasi, N. D'Alessandro (Palermo) |
| P-11/22 | Structure
Activity Relation of rigid analogues of Combretastatin A4, a tubulin
depolymerizing agent with antutumoral activity A. Caldarelli, S. Theeramunkong , A. Massarotti, D. Caprioglio, A. Teruggi, T. Pirali, PL. Canonico, G.C. Tron, AA. Genazzani (Novara) |
| P-11/23 | Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion
and migration of colon cancer cells R. Minelli, P. Pettazzoni, L. Serpe, G. Barrera, R. Fantozzi, GP. Zara, C. Dianzani (Torino) |
| P-11/24 | Novel inhibitors of microsomal prostaglandin E synthase-1
suppress tumor growth and angiogenesis E. Terzuoli, S. Donnini, F. Finetti, I. Coletta , G. Mangano, A. Giachetti, L. Polenzani, M. Ziche (Siena, Roma) |
| P-11/25 | Pharmacogenomic
markers of clinical efficacy in a dose-dense therapy
regimen (R-CHOP14) in diffuse large B cell lymphoma: preliminary results C. Napoli, S. Nobili, I. Landini, G. Perrone, B. Puccini, G. Antognoli , M. Doria, M. Martelli, E. Finolezzi, L. Rigacci, S. Di Lollo, A. Bosi, E. Mini (Firenze, Roma) |
| P-11/26 | A newest Cetuximab-based bio-chemo-immunotherapy regimen enhances
antigen presentation and cytotoxic T cell activity in advanced colorectal cancer
patients E. Bestoso, C. Botta, S. Apollinari, L. Micheli, G. Giorgi, P. Correale (Siena) |
| P-11/27 | Bevacizumab impairs the activity
of the major VEGF-carrier cells: neutrophils and platelets C. Botta, E. Bestoso, S. Apollinari, D. Cerretani, G. Giorgi, P. Correale ( Siena) |
| P-11/28 | Characterization of nicotinamide
phosphoribosyl transferase Inhibitors as anticancer agents C. Travelli, U. Galli, GC. Tron, PL. Canonico, A.A. Genazzani (Novara) |
| P-11/29 | Selumetinib sensitivity in human
colorectal cancer and non-small cell lung cancer. L.P. Ciuffreda, S. Costantino, T. Troiani, R. Russo, E. Martinelli, F. Ciardiello, F. Rossi, L. Berrino (Napoli) |
| P-11/30 | 5-Aminolevulinic Acid and High
Energy Shock Waves for Sonodynamic Therapy: effects on SK-N-BE and SH-SY5Y
neuroblastoma cell lines L. Serpe, R. Canaparo, F. Foglietta, GP. Zara, M. Eandi, C. Ferretti, R. Frairia (Torino) |
| P-11/31 | In Vitro Anticancer Activity of Hemidesmus Indicus in Human Leukemia Cells: Cellular
and Molecular Pathways. M. Lenzi, C. Fimognari, L. Ferruzzi, E. Turrini, G. Cantelli-Forti, P. Hrelia (Bologna) |
| P-11/32 | Chemopreventive
effects of cannabidiol and role of the endocannabinoid system in a model of carcinogenic-induced colon cancer G. Aviello, B. Romano , F. Borrelli, R. Capasso, F. Piscitelli, P. Orlando, S. Pace, F. Capasso , V. Di Marzo, A.A. Izzo (Naples, Pozzuoli, Naples) |
| P-11/33 | Molecular
imaging by micro-PET to evaluate the antitumoral activity of natural
molecules for the treatment of alveolar rhabdomyosarcoma E. Bergantin, C. Quarta , C. Nanni, S. Fanti, A. Pession, G. Cantelli-Forti, P. Hrelia, R. Tonelli (Bologna) |
| P-11/34 | Generation of bioluminescent
Medulloblastoma mouse models and identification of different tumor
progressions in the desmoplastic, classic and anaplastic variants. E. De Marco, C. Camerin, L. Mezzanotte, A. Roda, A. Pession, P. Hrelia, R. Tonelli (Bologna) |
| P-11/35 | BMYB: a new potential target for
the therapy of MYCN-amplified neuroblastoma tumors |
| P-11/36 | Characterization of the effects of
celecoxib and 2,5 di-methylcelecoxib on human
Chronic Myeloid Leukemia B. Riva, F. Condorelli, PL.. Canonico (Novara) |
| P-11/37 | A novel mechanism of action of
RDC11: the targeting of the HIF-1 and mTOR pathways. V. Vidimar, D. Guenot, M. Pfeffer, A. Bergamo, G. Sava, JP. Loeffler, C. Gaiddon ( Trieste, |